ALK and non-small cell lung carcinoma: The ALTA-1 L trial and EXP-3B arm of NCT01970865 trial demonstrated that use of brigatinib and lorlatinib in the first line and subsequent line therapy of ALK-positive NSCLC substantially reduced the risk of disease progression (24, 28).